The mode of action of IL-33/ST2 in solid tumors is predominantly driven by type-2 tumor-associated macrophages (TAM), as has been shown in colorectal cancers, squamous cell carcinoma, and ovarian cancers59–61. This evidence concerns the gene IL1RL1 and squamous cell carcinoma.